Crossmark

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients

Crossref DOI link: https://doi.org/10.1186/S40064-016-3024-5

Published: 2016-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Hallinen, Taru

Soini, Erkki J.

Linna, Miika

Saarni, Samuli I.
Funding

Funding for this research was provided by:

Pfizer Oy

Oy Bristol-Myers Squibb (Finland) Ab
License Information

unspecified valid from 2016-08-17